Cm. Wischik et al., MOLECULAR DETERMINANTS OF PAIRED HELICAL FILAMENT ASSEMBLY AND ITS THERAPEUTIC IMPLICATIONS IN ALZHEIMERS-DISEASE, International review of psychiatry, 7(3-4), 1995, pp. 299-338
Studies of Alzheimer's disease have pointed to loss of the normal micr
otubule associated protein tau and accumulation of pathological paired
helical filaments as strong discriminators for cognitive impairment.
The most likely explanation is that the redistribution of tau protein
into PHFs is associated with a failure of axonal transport in cortico-
cortical association circuits through failure to maintain axonal tubul
in in the polymerized state within pyramidal cells. Current understand
ing of and attempts to translate the key pathogenetic steps in tau pat
hology as they occur in the human brain are reviewed. Although the pho
sphorylation hypothesis has dominated the application of molecular and
cell biological methods, there are substantial difficulties with this
account when it has been tested in clinico-pathological studies. The
present review develops a more pragmatic view of PHF assembly, that it
is in principle an amyloidosis, since more than 80% of the tau protei
n found PHFs is in the form of detergent insoluble protease-resistant
polymers of molecules which have undergone substantial proteolytic pro
cessing in the course of polymerization. These molecules have also und
ergone a characteristic conformational shift in the course of polymeri
zation, and acquire binding sites for planar dyes. The theoretical sta
nce which best fits this data is that which has been proposed in the P
rion diseases. A variety of factors may act to initiate a pathological
conformational change which is then propagated because of the capacit
y of the modified form of the molecule to seed the polymerization of t
he normal form. Whatever the ultimate causes, the process can be shown
to progress exponentially in the human brain. Pharmaceutical blockade
of pathological redistribution of tau protein into PHFs would represe
nt a desirable pharmaceutical target, since it is likely to represent
a major component of the final common molecular substrate of clinical
dementia of the Alzheimer-type.